Business Description
Pyxis Oncology Inc
NAICS : 325412
SIC : 2834
ISIN : US7473241013
Total Employee Number:
56Description
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.25 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.58 | |||||
Debt-to-EBITDA | -0.22 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -10.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 29.8 | |||||
3-Year EPS without NRI Growth Rate | 29.5 | |||||
3-Year FCF Growth Rate | 29.3 | |||||
3-Year Book Growth Rate | -43 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 1.11 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.01 | |||||
9-Day RSI | 63.56 | |||||
14-Day RSI | 63.78 | |||||
3-1 Month Momentum % | 15.54 | |||||
6-1 Month Momentum % | 48.7 | |||||
12-1 Month Momentum % | 42.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.76 | |||||
Quick Ratio | 2.76 | |||||
Cash Ratio | 2.48 | |||||
Days Sales Outstanding | 79.02 | |||||
Days Payable | 1158.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.5 | |||||
Shareholder Yield % | 0.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.77 | |||||
Operating Margin % | -619.61 | |||||
Net Margin % | -589.8 | |||||
EBITDA Margin % | -587.73 | |||||
FCF Margin % | -458.23 | |||||
OCF Margin % | -458.23 | |||||
ROE % | -118.73 | |||||
ROA % | -78.51 | |||||
ROIC % | -358.28 | |||||
3-Year ROIIC % | -745.15 | |||||
ROC (Joel Greenblatt) % | -427.35 | |||||
ROCE % | -99.53 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 11.92 | |||||
PB Ratio | 5.29 | |||||
Price-to-Tangible-Book | 5.27 | |||||
EV-to-EBIT | -1.68 | |||||
EV-to-EBITDA | -1.77 | |||||
EV-to-Revenue | 10.4 | |||||
EV-to-Forward-Revenue | 823.89 | |||||
EV-to-FCF | -2.27 | |||||
| Price-to-Net-Current-Asset-Value | 13.18 | |||||
| Price-to-Net-Cash | 20.27 | |||||
Earnings Yield (Greenblatt) % | -59.52 | |||||
FCF Yield % | -38.04 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PYXS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pyxis Oncology Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 13.858 | ||
| EPS (TTM) ($) | -1.31 | ||
| Beta | 1.3135 | ||
| 3-Year Sharpe Ratio | 0.39 | ||
| 3-Year Sortino Ratio | 0.73 | ||
| Volatility % | 141.23 | ||
| 14-Day RSI | 63.78 | ||
| 14-Day ATR ($) | 0.30446 | ||
| 20-Day SMA ($) | 2.1075 | ||
| 12-1 Month Momentum % | 42.5 | ||
| 52-Week Range ($) | 0.97 - 5.55 | ||
| Shares Outstanding (Mil) | 63.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pyxis Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pyxis Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-03 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 40 days | ||
| General meeting for 2026 | 2026-06-15 10:00 | 1.76 (+4.14%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 07:35 | 1.70 (-1.73%) | ||
| Stifel Virtual Oncology | 2026-05-20 15:30 | 1.91 (-4.98%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-19 14:35 | 2.02 (-9.42%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 2.21 (-16.60%) | ||
| Annual report for 2025 | 2026-03-23 | 1.47 (-4.55%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 1.47 (-4.55%) | ||
| Pyxis Oncology MICVO R/M HNSCC Clinical Update | 2025-12-18 08:30 | 3.37 (-15.96%) |
Show
Entries
Pyxis Oncology Inc Frequently Asked Questions
What is Pyxis Oncology Inc(PYXS)'s stock price today?
The current price of PYXS is $2.64. The 52 week high of PYXS is $5.55 and 52 week low is $0.97.
When is next earnings date of Pyxis Oncology Inc(PYXS)?
The next earnings date of Pyxis Oncology Inc(PYXS) is 2026-08-14 Est..
Does Pyxis Oncology Inc(PYXS) pay dividends? If so, how much?
Pyxis Oncology Inc(PYXS) does not pay dividend.
Guru Commentaries on NAS:PYXS
No articles.
Press Release
Articles on Pyxis Oncology Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers